SC
AGIO icon

SummitTX Capital’s Agios Pharmaceuticals AGIO Stock Holding History

SummitTX Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-262,977
Closed -$10.6M – 681
2025
Q3 		$10.6M Buy
+262,977
New +$9.89M 0.44% 46
2025
Q2 		– Sell
-10,768
Closed -$316K – 729
2025
Q1 		$316K Buy
+10,768
New +$357K 0.01% 649

Other funds holding AGIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

SummitTX Capital's AGIO Position: Q4 2025 in Review

SummitTX Capital sold out of Agios Pharmaceuticals (AGIO) in Q4 2025, closing a stake of 262,977 shares — an estimated $10.6M sold.

SummitTX Capital first reported a position in AGIO in Q1 2025 and held it in 2 quarters. The position peaked at $10.6M in Q3 2025. 238 funds tracked by Wall St. Rank hold AGIO as of Q4 2025.

  • SummitTX Capital reported no remaining Agios Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • SummitTX Capital sold 262,977 Agios Pharmaceuticals shares in Q4 2025, an estimated $10.6M.
  • SummitTX Capital first reported a position in Agios Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • SummitTX Capital's Agios Pharmaceuticals position peaked at $10.6M in Q3 2025.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2025.

Based on SummitTX Capital's 13F filing for Q4 2025, filed 17 Feb 2026.